#Israel #Tel Aviv #RNA Delivery #Mana.bio #Laura Sepp-Lorenzino

Mana.bio Welcomes Laura Sepp-Lorenzino to Advisory Board

Mana.bio, a pioneering company in the biotechnology sector, specializes in transforming RNA delivery through innovative approaches driven by artificial intelligence. The company has proudly announced the recent appointment of Laura Sepp-Lorenzino to its Scientific Advisory Board. This strategic addition comes at a crucial stage of Mana.bio's expansion, emphasizing the expertise that Dr. Sepp-Lorenzino brings to the table.

A Prominent Figure in Genetic Medicine

Dr. Laura Sepp-Lorenzino is an esteemed figure in the world of genetic medicine. Her distinguished career is marked by significant advancements in the development of innovative therapies. Previously, she served as Chief Scientific Officer at Intellia Therapeutics, where she led initiatives that propelled the company's CRISPR-based therapies. Before her tenure at Intellia, Dr. Sepp-Lorenzino held key leadership roles at both Vertex Pharmaceuticals and Alnylam Pharmaceuticals. Her extensive experience, particularly in advancing complex therapeutic modalities from research phases to clinical settings, is expected to play a vital role in supporting Mana.bio's ongoing projects.

Yogev Debbi, Co-Founder and CEO of Mana.bio, expressed his enthusiasm for Dr. Sepp-Lorenzino’s appointment, noting, "We are honored to welcome Laura to our Scientific Advisory Board at this pivotal stage of our company's growth. Her deep scientific fluency and experience are invaluable as we scale our AI-driven lipid nanoparticle (LNP) discovery engine and expand our therapeutic pipeline."

Enhancing AI-Driven Therapeutics

Mana.bio utilizes a sophisticated AI/ML platform to enhance RNA delivery mechanisms through the discovery of lipid nanoparticles. With access to the largest curated dataset on LNPs, the company is positioned to make accurate predictions about safety and efficacy in genetic therapies. Dr. Sepp-Lorenzino’s insights are expected to help refine these technologies and develop solutions that can significantly improve patient outcomes.

Currently, Mana.bio has developed a predictive safety model designed to mitigate risk during the LNP design process, addressing one of the major bottlenecks in RNA therapeutic advancement. Such innovations underscore Mana.bio's commitment to bringing transformative genetic medicines to the global market.

A Legacy of Leadership and Innovation

Dr. Sepp-Lorenzino is not just a leader in her field but has also made substantial contributions to various organizations within the industry. She currently serves on several boards, including Taysha Gene Therapies, Asklepios Biopharmaceutical, Lexeo Therapeutics, and URSA Medicines. Her involvement with the Oligonucleotide Therapeutics Society (OTS) and the American Society of Cell and Gene Therapy (ASGCT) further highlights her influence in shaping the future of genetic medicine. Dr. Sepp-Lorenzino holds a professional degree in Biochemistry from the University of Buenos Aires, along with an M.S. and Ph.D. in Biochemistry from New York University.

Conclusion

The addition of Laura Sepp-Lorenzino to Mana.bio’s Scientific Advisory Board is a testament to the company's commitment to advancing RNA delivery technologies. As Mana.bio continues to leverage AI capabilities to unravel the complexities of genetic medicine, the expertise of industry veterans like Dr. Sepp-Lorenzino will undoubtedly be instrumental in achieving its goals. The future of personalized therapies looks promising with innovators at the helm, and Mana.bio is set to lead in this dynamic landscape of biotechnology.